What drove the significant revenue increase in the third quarter?

The substantial revenue increase of 26.9% was driven by a combination of factors. This included a strong increase in volume across all business segments (Medical, Life Sciences, and Interventional), benefiting from the recovery of elective medical procedures. Additionally, significant contributions came from COVID-19 diagnostic testing solutions offered by the Life Sciences segment, and a favorable foreign currency translation impact of approximately 4.9%.

What is the strategic rationale behind the planned spin-off of the Diabetes Care business?

Becton Dickinson announced its intention to spin off its Diabetes Care business as a separate publicly traded company. The primary rationale is that as an independent entity, the Diabetes Care business will be better positioned to allocate its capital and operational resources with a dedicated growth strategy, potentially unlocking greater value for shareholders and allowing BDX to focus on its core businesses.

How are the product liability matters impacting the company's financial results?

The company recorded a pre-tax charge of $296 million in the nine months ended June 30, 2021, related to certain product liability matters, specifically concerning Hernia Product Claims and other legal disputes. While this charge impacted the current period's results, the company has established accruals totaling approximately $2.5 billion for product liability claims. These ongoing legal matters represent a significant contingent liability that investors should monitor.

What is the outlook for the company, considering the ongoing COVID-19 pandemic and other challenges?

The company acknowledges the ongoing impact of the COVID-19 pandemic, which can lead to volatility in demand and supply chain disruptions. However, BDX sees opportunities in providing COVID-19 diagnostic solutions and serving the recovery in healthcare utilization. The company is focused on its 'grow, simplify, and empower' strategy. Despite legal and regulatory challenges, the diversified nature of its business segments and strategic initiatives like the spin-off provide a foundation for future growth and value creation.

BDX 10-Q Quarterly Report Q3 FY2021 — Revenue, Net Income, EPS

Summary

Becton Dickinson & Co. (BDX) reported a strong financial performance for the quarter ending June 30, 2021, with revenues increasing significantly by 26.9% year-over-year to $4.89 billion. This growth was driven by a broad-based increase in volume across its Medical, Life Sciences, and Interventional segments, with notable contributions from COVID-19 diagnostic testing solutions and a recovery in elective medical procedures. The company's profitability also saw a substantial improvement, with net income more than doubling to $525 million compared to $286 million in the prior-year period. Diluted Earnings Per Share (EPS) rose to $1.72 from $0.97. The company generated robust operating cash flow of $3.7 billion for the nine months ended June 30, 2021, demonstrating strong operational efficiency and financial discipline. BDX also announced its intention to spin off its Diabetes Care business in the first half of calendar year 2022, a strategic move aimed at unlocking value and focusing resources. However, investors should note the ongoing legal and regulatory matters, particularly product liability claims related to hernia repair devices and other products, which led to a significant charge of $296 million in the current quarter. While the company is actively managing these issues, they represent a material contingent liability. Despite these challenges, the company's diversified business segments and strategic initiatives, including the planned spin-off, position it for continued growth and value creation.

Financial Highlights

53 data points

Beta

Revenue

$4.61B

0.4% Gross Margin

Net Income

$525.00M

0.1% Net Margin

EPS (Diluted)

$1.72

Total Assets

$54.33B

Cash & Equivalents

$3.15B

Free Cash Flow

$732.00M

Financial Statements

Beta

Revenue	$4.61B
Cost of Revenue	$2.65B
Gross Profit	$1.96B
R&D Expenses	$330.00M
SG&A Expenses	$1.20B
Operating Expenses	$4.11B
Operating Income	$492.00M
Interest Expense	$115.00M
Net Income	$525.00M
EPS (Basic)	$1.73
EPS (Diluted)	$1.72
Shares Outstanding (Basic)	289.52M
Shares Outstanding (Diluted)	291.90M

Key Highlights

1Revenue surged 26.9% to $4.89 billion, driven by strong volume growth across all segments, aided by COVID-19 related testing and recovery in medical procedures.
2Net income more than doubled to $525 million, and Diluted EPS rose to $1.72, reflecting improved operational performance and revenue growth.
3Operating cash flow remained robust at $3.7 billion for the nine months ended June 30, 2021, indicating strong cash generation capabilities.
4The company announced its intention to spin off its Diabetes Care business in the first half of calendar year 2022 to create a standalone entity.
5A significant product liability charge of $296 million was recorded for Hernia Product Claims and other matters, highlighting ongoing legal contingencies.
6Investment in Research and Development (R&D) increased as a percentage of revenue in the Medical and Interventional segments, signaling a commitment to future innovation.
7The company's debt structure saw a shift with an increase in short-term debt as a percentage of total debt due to reclassification of certain notes.

BECTON DICKINSON & CO Quarterly Report for Q3 Ended Jun 30, 2021

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions